Heart-Safe chemo? trial aims to shield patients from lifelong damage

This study tests two different drugs—dexrazoxane and liposomal doxorubicin—to see which is safer and more effective at preventing heart failure in people with a type of lymphoma called DLBCL. All 60 participants will receive standard chemotherapy (R-CHOP or pola-R-CHP), and the goal is to find a way to protect the heart without reducing the cancer treatment's power. The trial is for newly diagnosed patients who are at high risk for heart problems.